Florencia Aliverti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Florencia Aliverti has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Buchamer
Universidad Nacional de La Plata, Facultad de Ciencias Veterinarias, La Plata, Argentina
2 shared publications - Daniel Buldain
Universidad Nacional de La Plata, Facultad de Ciencias Veterinarias, La Plata, Argentina
2 shared publications - Karen Julca Lozano
Universidad Nacional de La Plata, Facultad de Ciencias Veterinarias, La Plata, Argentina
2 shared publications - Lihuel Gortari Castillo
Universidad Nacional de La Plata, Facultad de Ciencias Veterinarias, La Plata, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
2 shared publications - María Laura Marchetti
Universidad Nacional de La Plata, Facultad de Ciencias Veterinarias, La Plata, Argentina
2 shared publications - Alan Paris
Laboratorio de Estudios Farmacológicos y Toxicológicos (LEFyT), Facultad de Ciencias Veterinarias, Universidad Nacional de La Plata, La Plata 1900, Argentina
1 shared publication
Latest Publications
- Open Access
- 1 November 2026
- Published by American Dairy Science Association in Journal of Dairy Science
- Vol. 109 (11) , 11946-11963
Metrics and monitoring of antimicrobial use in dairy production in Argentina
To address the rising threat of antimicrobial resistance, many countries are making efforts to establish baseline data and monitor antimicrobial use (AMU) in livestock. Although international reporting uses the total mass of antimicrobial agents standardized by animal biomass, other metrics may be more useful for individual countries, farmers or veterinarians to monitor progress over time. Using garbage can audits, we collected observational data on on-farm AMU from a convenience sample of 29 Argentinian dairy farms, separated into adult and youngstock groups, and calculated mass- and course-based metrics to benchmark estimated usage over the first 365 d of collection. Aggregated data from all farms gave an overall average (mean) usage of 25.8 mg/PCU; when calculated per farm, median AMU was 19.37 mg/PCU (range 4.97 to 58.90 mg/PCU). The third-generation cephalosporin, ceftiofur, was widely used as an injectable in adult cattle, while enrofloxacin was commonly used in youngstock. Oral ciprofloxacin - marketed as part of a multivitamin preparation for use in newborn calves - while only found on 4 farms, constituted 34% of all Category B antimicrobials, recommended as restricted for use in livestock by the European Medicines Agency. Course-based metrics demonstrated that high medicine usage on individual farms tended to occur in only one of the following categories: Category B medicines, youngstock, intramammary or systemic treatment in adults. These granular metrics help identify problem areas for individual farms, but may be less useful for formulating policy and measuring progress. A reduction in Category B usage appears to be a good opportunity for improved stewardship for the majority of participants and potentially for similar intensifying farms in the Argentinian dairy sector, although country-specific data (such as actual course doses and lengths used in the country) would improve calculation methodology for national monitoring.
- 1 November 2026
- Published by American Dairy Science Association in Journal of Dairy Science
- Vol. 109 (11) , 11946-11963
Open AccessMetrics and monitoring of antimicrobial use in dairy production in Argentina
To address the rising threat of antimicrobial resistance, many countries are making efforts to establish baseline data and monitor antimicrobial use (AMU) in livestock. Although international reporting uses the total mass of antimicrobial agents standardized by animal biomass, other metrics may be more useful for individual countries, farmers or veterinarians to monitor progress over time. Using garbage can audits, we collected observational data on on-farm AMU from a convenience sample of 29 Argentinian dairy farms, separated into adult and youngstock groups, and calculated mass- and course-based metrics to benchmark estimated usage over the first 365 d of collection. Aggregated data from all farms gave an overall average (mean) usage of 25.8 mg/PCU; when calculated per farm, median AMU was 19.37 mg/PCU (range 4.97 to 58.90 mg/PCU). The third-generation cephalosporin, ceftiofur, was widely used as an injectable in adult cattle, while enrofloxacin was commonly used in youngstock. Oral ciprofloxacin - marketed as part of a multivitamin preparation for use in newborn calves - while only found on 4 farms, constituted 34% of all Category B antimicrobials, recommended as restricted for use in livestock by the European Medicines Agency. Course-based metrics demonstrated that high medicine usage on individual farms tended to occur in only one of the following categories: Category B medicines, youngstock, intramammary or systemic treatment in adults. These granular metrics help identify problem areas for individual farms, but may be less useful for formulating policy and measuring progress. A reduction in Category B usage appears to be a good opportunity for improved stewardship for the majority of participants and potentially for similar intensifying farms in the Argentinian dairy sector, although country-specific data (such as actual course doses and lengths used in the country) would improve calculation methodology for national monitoring.
- Open Access
- 5 January 2026
- Published by Open Exploration Publishing in Exploration of Drug Science
- Vol. 4, 1008138
Novel antimicrobial efficacy on inert surfaces of chlorhexidine-silver nanoparticle veterinary formulation
Aim: This study aimed to establish the in vitro efficacy of chlorhexidine (CHX)-silver nanoparticles (AgNP) based preparation, against Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (P. aeruginosa) in planktonic cultures, biofilms, and on inert stainless-steel surfaces. Methods: The in vitro antimicrobial activity of the CHX-AgNP formulation (Dermosedan MRSA Nano AG®) was evaluated against reference and multidrug-resistant (MDR) strains of S. aureus and P. aeruginosa by determining the minimum inhibitory and bactericidal concentrations (MIC and MBC), as well as the minimum biofilm inhibitory and eradication concentrations (MBIC and MBEC). Also, the residual bactericidal activity on inert stainless-steel surfaces was evaluated. Results: MIC against methicillin-resistant S. aureus (MRSA) and MDR P. aeruginosa (MDR-PA) isolates ranged between 5/2.5–20/10 µg/mL, up to 8,000 times lower than the manufacturer’s recommended concentration, while MBC ranged from 500 to 2,000 times lower. MBIC matched the MBC, while higher concentrations were needed to eradicate preformed biofilms. On stainless-steel surfaces, high antimicrobial activity was observed for both pathogens. No bacterial survival was detected even after 6 hours at 4% CHX + 2% AgNP concentration. The CHX-AgNP combination demonstrated strong antimicrobial and antibiofilm activity against both S. aureus and P. aeruginosa. Conclusions: These results support the potential application of Dermosedan MRSA Nano AG® as a strategy for managing topical resistant infections and for environmental disinfection in both veterinary and clinical settings.
- 5 January 2026
- Published by Open Exploration Publishing in Exploration of Drug Science
- Vol. 4, 1008138
Open AccessNovel antimicrobial efficacy on inert surfaces of chlorhexidine-silver nanoparticle veterinary formulation
Aim: This study aimed to establish the in vitro efficacy of chlorhexidine (CHX)-silver nanoparticles (AgNP) based preparation, against Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (P. aeruginosa) in planktonic cultures, biofilms, and on inert stainless-steel surfaces. Methods: The in vitro antimicrobial activity of the CHX-AgNP formulation (Dermosedan MRSA Nano AG®) was evaluated against reference and multidrug-resistant (MDR) strains of S. aureus and P. aeruginosa by determining the minimum inhibitory and bactericidal concentrations (MIC and MBC), as well as the minimum biofilm inhibitory and eradication concentrations (MBIC and MBEC). Also, the residual bactericidal activity on inert stainless-steel surfaces was evaluated. Results: MIC against methicillin-resistant S. aureus (MRSA) and MDR P. aeruginosa (MDR-PA) isolates ranged between 5/2.5–20/10 µg/mL, up to 8,000 times lower than the manufacturer’s recommended concentration, while MBC ranged from 500 to 2,000 times lower. MBIC matched the MBC, while higher concentrations were needed to eradicate preformed biofilms. On stainless-steel surfaces, high antimicrobial activity was observed for both pathogens. No bacterial survival was detected even after 6 hours at 4% CHX + 2% AgNP concentration. The CHX-AgNP combination demonstrated strong antimicrobial and antibiofilm activity against both S. aureus and P. aeruginosa. Conclusions: These results support the potential application of Dermosedan MRSA Nano AG® as a strategy for managing topical resistant infections and for environmental disinfection in both veterinary and clinical settings.